Pharmanutra

Transaction in Own Shares • Jan 24, 2022

Informazione Regolamentata n. 20106-8-2022		Data/Ora Ricezione 24 Gennaio 2022 18:38:15	Euronext Star Milan
Societa'	:	PHARMANUTRA
Identificativo Informazione Regolamentata	:	156596
Nome utilizzatore	:	PHARMANUTRAN02 - Lacorte Roberto
Tipologia	:	2.4
Data/Ora Ricezione	:	24 Gennaio 2022 18:38:15
Data/Ora Inizio Diffusione presunta	:	24 Gennaio 2022 18:38:16
Oggetto	:	PR - PHARMANUTRA Initiation of share buy-back program
Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM

Pisa, 24th January 2022 – PharmaNutra S.p.A. (MTA; Ticker PHN), a group of companies specialised in mineral supplements and medical devices for muscles and joints, announces the beginning of a share buyback program, previously authorized by the Shareholders' Meeting of April 26 th, 2021.

The program is aimed at allowing the Company to seize the opportunity to make an advantageous investment, in cases where the market price of PHN shares, also due to factors external to the Company, is not able to adequately express the value of the same, and therefore to provide the Company with a useful strategic investment opportunity for all purposes permitted by current regulations.

The purchase of shares within the scope of the programme is done with the modalities and within the operating limits laid down in the decision referred to above, by Article 5 of (EU) Regulation no. 596/2014 (Market Abuse Regulation), by Article 3 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 and by the general and industry legislation in force, in particular:

• purchases will be for a maximum overall of 15.000 ordinary shares of the Company without indication of nominal value to a maximum value of EUR 1,050,000;
• such purchases will be made with a consideration that is not higher than the highest price of the last independent operation and the highest current independent bid on the trading venues where the purchase is carried out, it being understood that the price cannot be lower than a minimum of 20% or higher than a maximum of 10% than the stock price registered at the close of the trading session prior to each single purchase transaction;
• such purchases will be made for quantities not exceeding 25% of the average daily volume of PHN shares in the trading venue where the purchase is carried out, calculated on the basis of the average daily volume traded in the 20 trading days prior to the date of purchase;
• the purchase programme will be realized within 18 months from the date of the Shareholders' Meeting of 26 April 2021.

Intermonte SIM S.p.A. operates as an intermediary responsible for purchases within the scope of the programme. The Company will provide information with regard to the transactions relating to the programme for the purchase of own shares, in accordance with the terms and conditions required by the applicable regulation. Any subsequent change to the above-described buy-back plan will be promptly disclosed by the Company.

As at the date of this press release, PharmaNutra does not hold treasury shares in portfolio.

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra, established in 2003, develops unique nutraceuticals and innovative medical devices, overseeing the entire production process from the proprietary raw materials to the finished product. PharmaNutra is the leading producer, with the SiderAL® trademark, of iron-based nutritional supplements, a field where it holds important patents on Sucrosomial® Technology and is regarded as one of the top emerging players in medical devices for the rehabilitation of joint capacity thanks to the Cetilar brand. The effectiveness of its products has been demonstrated by extensive scientific evidence, including more than 120 published papers. In Italy, sales are conducted through a network of more than 160 medical representatives, who also handle exclusive marketing of PharmaNutra products to pharmacies and parapharmacies all over the country. International sales in more than 50 countries are managed through 37 partners selected from top pharmaceutical companies. Over the years, the Group has developed a specific intellectual property production and management strategy, based on integrated management of all components: proprietary raw materials, patents, trademarks and clinical data. PharmaNutra.it

For further information:

Via Delle Lenze, 216/b - 56122 Pisa Tel. +39 050 7846500 investorrelation@PharmaNutra.it

Internal Press Office press@calabughi.com

PharmaNutra S.p.A. Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708

Matteo Russo mrusso@sprianocommunication.com Cristina Tronconi ctronconi@sprianocommunication.com